CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 60 enrolled
Drug / intervention
Azithromycin +1 moredrug
Likely dose
Azithromycin 5 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02544984
NCT02544984N/ACompleted
CompareCT.gov

The Anti-inflammatory Effect of Prophylactic Macrolides on Children With Chronic Lung Disease: a Double Blinded RCT

The University of Texas Health Science Center, Houston·interventional·Posted Sep 9, 2015·Updated Jun 6, 2018

In Brief

A clinical study evaluating Azithromycin and placebo for Chronic Lung Disease. Completed, enrolled 60 participants across 1 site.

Detailed Summary

The purpose of this study is to determine if the prophylactic use of azithromycin will reduce the total number of days when unscheduled treatment is given outside of the home in a clinic, urgent care, emergency room or hospital setting between the respiratory illness season months (October 1-March 31) and subsequent 2 month follow-up (April and May)

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Lung Disease
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedSep 9, 2015
Enrollment StartOct 1, 2015
Primary CompletionMar 31, 2017
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 10.8 years ago

Interventions

Azithromycindrug

Patients will receive azithromycin at a dose of 5 mg/kg to be given once a day on Monday, Wednesday, and Friday. The dosage will not be adjusted if a new weight is obtained during the trial period.

placebodrug

Patients will receive placebo at a dose of 5 mg/kg to be given once a day on Monday, Wednesday, and Friday. The dosage will not be adjusted if a new weight is obtained during the trial period.